出血性脑卒中患者的肾脏清除率增强
这项前瞻性观察研究在三级学术医疗中心神经科学ICU纳入50例动脉瘤性蛛网膜下腔出血和30例脑出血患者,每日进行8小时尿收集实测肌酐清除率,并与Cockcroft-Gault公式计算的肌酐清除率和MDRD公式估算的肾小球滤过率比较。动脉瘤性蛛网膜下腔出血患者平均实测肌酐清除率147.9±50.2 mL/min/1.73 m,高于Cockcroft-Gault计算值109.1±32.7(p<0.0001)和MDRD估算值126.0±41.9(p=0.04);94%的患者至少1天出现肾脏清除率增强。脑出血患者平均实测肌酐清除率119.5±57.2,高于Cockcroft-Gault计算值77.8±27.6(p<0.0001)和MDRD估算值93.0±32.8(p=0.02);50%的患者至少1天出现肾脏清除率增强。作者认为肾脏清除率增强可能导致经肾排泄药物浓度低于治疗水平,造成治疗失败等并发症。
要点
- 动脉瘤性蛛网膜下腔出血患者平均实测肌酐清除率147.9±50.2 mL/min/1.73 m,高于Cockcroft-Gault计算值109.1±32.7(p<0.0001)。
- 94%的动脉瘤性蛛网膜下腔出血患者至少1天出现肾脏清除率增强(实测肌酐清除率≥130 mL/min/1.73 m)。
- 脑出血患者平均实测肌酐清除率119.5±57.2 mL/min/1.73 m,高于Cockcroft-Gault计算值77.8±27.6(p<0.0001)。
- 50%的脑出血患者至少1天出现肾脏清除率增强。
- 作者认为肾脏清除率增强可能导致经肾排泄药物浓度低于治疗水平,造成治疗失败等并发症。
适用人群与场景
- 纳入标准:入院诊断为动脉瘤性蛛网膜下腔出血或脑出血,预计神经科学ICU住院时间超过48小时,入院血清肌酐<1.5 mg/dL,无慢性肾脏病病史。
- 排除标准:有肾脏功能障碍证据(入院血清肌酐≥1.5 mg/dL)或慢性肾脏病病史。
- 研究场景:三级学术医疗中心神经科学ICU。
诊断标准与关键阈值
- 肾脏清除率增强定义:实测肌酐清除率大于Cockcroft-Gault公式计算的肌酐清除率且大于MDRD公式估算的肾小球滤过率。
- 肾脏清除率增强(augmented renal clearance)定义:实测肌酐清除率≥130 mL/min/1.73 m。
研究设计与关键结果
- 研究类型:前瞻性观察性研究;样本量:50例动脉瘤性蛛网膜下腔出血和30例脑出血患者,共590次独立测量;设置:三级学术医疗中心神经科学ICU。
- 动脉瘤性蛛网膜下腔出血患者平均实测肌酐清除率147.9±50.2 mL/min/1.73 m,高于Cockcroft-Gault计算值109.1±32.7(p<0.0001),也高于MDRD估算值126.0±41.9(p=0.04)。
- 94%的动脉瘤性蛛网膜下腔出血患者至少1天出现肾脏清除率增强。
- 脑出血患者平均实测肌酐清除率119.5±57.2 mL/min/1.73 m,高于Cockcroft-Gault计算值77.8±27.6(p<0.0001),也高于MDRD估算值93.0±32.8(p=0.02)。
- 50%的脑出血患者至少1天出现肾脏清除率增强。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肾脏清除率增强可能导致经肾排泄药物浓度低于治疗水平,造成治疗失败和其他医疗并发症。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate enhanced renal clearance over time in patients with aneurysmal subarachnoid hemorrhage or intracerebral hemorrhage via measured creatinine clearance and to compare measured creatinine clearance to creatinine clearance calculated by the Cockcroft-Gault equation and estimated glomerular filtration rate calculated by the Modification of Diet in Renal Diseases equation.
DESIGN: Prospective, observational study.
SETTING: Neurosciences ICU in a tertiary care academic medical center.
PATIENTS: Study participants had an admission diagnosis of aneurysmal subarachnoid hemorrhage or intracerebral hemorrhage, an expected neurosciences ICU length of stay greater than 48 hours, no evidence of renal dysfunction (admission serum creatinine < 1.5 mg/dL), and no history of chronic kidney disease.
INTERVENTIONS: Eight-hour urine collections to measure creatinine clearance were collected daily as the primary method of measuring renal function. Creatinine clearance was also calculated using the Cockcroft-Gault equation and estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease equation. Enhanced renal clearance was defined as a measured creatinine clearance greater than the calculated creatinine clearance via Cockcroft-Gault and estimated glomerular filtration rate via Modification of Diet in Renal Disease. Augmented renal clearance was defined by a measured creatinine clearance greater than or equal to 130 mL/min/1.73 m. Relevant demographic, clinical, and outcome data were recorded.
MEASUREMENTS AND MAIN RESULTS: Fifty aneurysmal subarachnoid hemorrhage patients and 30 intracerebral hemorrhage patients were enrolled, contributing 590 individual measurements. Patients with aneurysmal subarachnoid hemorrhage had a higher mean measured creatinine clearance compared with the mean calculated creatinine clearance based on the Cockcroft-Gault equation (147.9 ± 50.2 vs 109.1 ± 32.7 mL/min/1.73 m; p < 0.0001) and higher mean measured creatinine clearance compared with the mean calculated estimated glomerular filtration rate based on the Modification of Diet in Renal Disease equation (147.9 ± 50.2 vs 126.0 ± 41.9 mL/min/1.73 m; p = 0.04). Ninety-four percent of participants with aneurysmal subarachnoid hemorrhage experienced augmented renal clearance on at least 1 day. In patients with intracerebral hemorrhage, there was a higher mean measured creatinine clearance over the study period compared with the mean calculated creatinine clearance (119.5 ± 57.2 vs 77.8 ± 27.6 mL/min/1.73 m; p < 0.0001) and higher mean measured creatinine clearance compared with the mean calculated estimated glomerular filtration rate based on the Modification of Diet in Renal Disease equation (119.5 ± 57.2 vs 93.0.0 ± 32.8 mL/min/1.73 m; p = 0.02). Fifty percent of participants with intracerebral hemorrhage experienced augmented renal clearance on at least 1 day.
CONCLUSIONS: A substantial group of patients with aneurysmal subarachnoid hemorrhage or intracerebral hemorrhage experienced enhanced renal clearance, which may be otherwise unknown to clinicians. Enhanced renal clearance may lead to increased renal solute elimination over what is expected, resulting in subtherapeutic renally eliminated drug concentrations. This may result in underexposure to critical medications, leading to treatment failure and other medical complications.
参考来源
- Morbitzer KA, Jordan JD, Dehne KA, et al. Enhanced Renal Clearance in Patients With Hemorrhagic Stroke. Crit Care Med. 2019. PMID: 30870191. doi:10.1097/CCM.0000000000003716
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。